Overall verdict
Buy
7.2/10
1-year performance
+31.30%
Score breakdown
Up 31.3% over 1 year, 89% of the 52-week range.
Strongest: Profitability 8.2/10. Weakest: Shareholder return 5.8/10.
18 analysts, target +0.1% vs the price.
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment, accident and health, vision, and pet insurance, as well as prepaid legal plans ;
administrative services-only arrangements to employers ; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products ; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives.
In addition, it offers fixed, indexed-linked, and variable annuities ; pension products ; regular savings products ; whole and term life, endowments, universal and variable life, and group life products ; longevity and funded reinsurance solutions ; credit insurance products ; accident & health products covering hospitalization, cancer, critical illness, income protection, and scheduled medical reimbursement plans ; and protection against long-term health care services. The company was incorporated in 1999 and is based in New York, New York.
Sector
Financials
Industry
Insurance
Primary listing
Nyse
United States
CEO
Michel Khalaf
Founded
1999
Employees
46 000
Revenue / employee
1.7M USD
Next earnings
February 3, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC1.97%
- FMR LLC0.96%
- Bank of New York Mellon Corp0.55%
- Rest of the register96.53%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
106.72 USD
52-week low
67.33 USD
1-year performance
31.30%
Rising
Year-to-date performance
29.45%
Rising
Drawdown
-4.24%
Near its high
Position in the 52-week range
89% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 2.0 times harder.
$10,000 placed at the end of December 2000 are worth today
| MetLife | $59,007 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 2.0 times as much as the world ETF.
- Worst fall:-73 % between September 2007 and February 2009. $10,000 placed at the top fell to $2,734. The world ETF, at worst: -53 %. Back to its high in 100 months.
MetLife earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- MetLife: $59,007
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 87.92 USD - 131.00 USD (2 methods agree)
The price implies growth of -16.36% per year; the company grows at -3.68%.
Net margin 6.2%, ROE 20.0%.
Net margin
6.18%
Fair
Sector 6.54%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
20.04%
Exceptional
Sector 12.03%|S&P 17.06%
Return on invested capital (ROIC)
11.07%
Free cash flow margin (FCF)
18.09%
Profit-to-cash conversion (FCF conversion)
2.93x
Margin stability
2.6 pts
Steady
Revenue to net income
Growth
6.2/10Revenue up 19.4% over 1 year, 2.6% a year over 5, EPS -3.7% a year over 5.
Revenue (trailing 12 months)
82.9Md USD
Revenue growth (1y)
19.38%
Hyper-growth
Revenue growth (3y)
12.09%
Moderate
EPS growth (1y)
200.53%
Hyper-growth
EPS CAGR (5y)
-3.68%
Declining
EPS revisions (3 months)
2.88%
Revised up
Valuation
7.5/10P/E 13.3x, forward P/E 11.9x, PEG 0.30. The multiple sits in the 82th percentile of its own 5-year history.
P/E (TTM)
13.3x
Fair
Sector 13.7x|S&P 23.6x
Forward P/E
11.9x
Fair
EV / EBITDA
—
Sector 79.1x|S&P 15.5x
PEG
0.30
Growth unpriced
Sector 0.96|S&P 0.91
Fair value (reverse DCF)
111.00 USD
Fairly priced
P/E vs its own 5-year history
among the 18% highest valuations
At its historical high
Market cap
64.2Md USD
Not scored for a bank or an insurer: its solidity is measured by regulatory capital ratios, which we do not collect.
Net debt / EBITDA
—
Gearing (net debt / equity)
9.43%
Cash
19.8Md USD
Cash / market cap
30.81%
Cash / total debt
90.23%
Interest coverage
4.2x
Net debt
2.1Md USD
Equity
22.7Md USD
Closed daily candles, 2 years
Last close on November 11, 2026: 102.94 USD
- MM20100.82
- MM5098.56
- MM20086.67
- RSI 1458.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.78%
200-day average slope, 3 months
+7.63%
50-day average slope, 1 month
+1.93%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.75 % per day
Volatility change
+28.38%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 8.59 (5) | 10.23 (17) | 79 451 (8) | — | 5 472 (4) |
| 2027 | 10.20 (7) | 11.18 (17) | 83 031 (8) | — | 6 536 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 81 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MET | 7.2 | 7.2 | 64.2Md USD | 13.3x | 6.2 % | 19.4 % | — | — | — | 31.3 % | ||
| 2 | 2628 | 7.1 | 8.8 | 132Md USD | 2.4x | 41.3 % | 36.2 % | — | — | — | -22.3 % | ||
| 3 | 601318 | 6.7 | 7.3 | 136Md USD | — | — | 6.5 % | — | — | — | -10.3 % | ||
| 4 | 1299 | 6.2 | 5.7 | 105Md USD | 13.3x | 23.2 % | 10.0 % | — | — | — | -4.8 % | ||
| 5 | LICI | 6.2 | 6.1 | 53.9Md USD | 8.2x | 6.1 % | 9.8 % | — | — | — | -10.3 % | ||
| 6 | MFC | 5.8 | 4.7 | 72.8Md USD | 18.1x | 10.3 % | -31.3 % | — | — | — | 35.3 % | ||
| 7 | GWO | 5.7 | 4.8 | 59.1Md USD | 19.6x | 11.4 % | -67.1 % | — | — | — | 59.3 % | ||
| 8 | 2881 | 5.5 | 4.7 | 65.1Md USD | 13.7x | 18.1 % | -2.8 % | — | — | — | 73.8 % | ||
| 9 | AFL | 4.4 | 3.8 | 62.9Md USD | 18.5x | 21.2 % | -31.0 % | — | — | — | 11.4 % |
